{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:23:00Z","timestamp":1790965380828,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["45\/15\/2022-PHA\/BMS"],"award-info":[{"award-number":["45\/15\/2022-PHA\/BMS"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Manipal Academy of Higher Education, Manipal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background and aim<\/jats:title>\n                <jats:p>Chronic myeloid leukemia is a myeloproliferative neoplasm associated with the specific chromosomal translocation known as the Philadelphia chromosome. Imatinib is a potent BCR-ABL tyrosine kinase inhibitor, which is approved as the first line therapy for CML patients. There are various population pharmacokinetic studies available in the literature for this population. However, their use in other populations outside of their cohort for the model development has not been evaluated. This study was aimed to perform the predictive performance of the published population pharmacokinetic models for imatinib in CML population and propose a dosing nomogram.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A systematic review was conducted through PubMed, and WoS databases to identify PopPK models. Clinical data collected in adult CML patients treated with imatinib was used for evaluation of these models. Various prediction-based metrics were used for assessing the bias and precision of PopPK models using individual predictions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Eight imatinib PopPK model were selected for evaluating the model performance. A total of 145 plasma imatinib samples were collected from 43 adult patients diagnosed with CML and treated with imatinib. The PopPK model reported by Menon et al. had better performance than all other PopPK models.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Menon et al. model was able to predict well for our clinical data where it had the relative mean prediction error percentage\u2009\u2264\u200920%, relative median absolute prediction error\u2009\u2264\u200930% and relative root mean square error close to zero. Based on this final model, we proposed a dosing nomogram for various weight groups, which could potentially help to maintain the trough concentrations in the therapeutic range.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00280-024-04644-w","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T09:02:38Z","timestamp":1709629358000},"page":"35-44","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Predictive performance of population pharmacokinetic models of imatinib in chronic myeloid leukemia patients"],"prefix":"10.1007","volume":"94","author":[{"given":"Jaya Shree","family":"Dilli Batcha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Gota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saikumar","family":"Matcha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun Prasath","family":"Raju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahadev","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik S.","family":"Udupa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2568-5096","authenticated-orcid":false,"given":"Surulivelrajan","family":"Mallayasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,5]]},"reference":[{"key":"4644_CR1","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","volume":"22","author":"B Peng","year":"2004","unstructured":"Peng B, Hayes M, Resta D et al (2004) Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 22:935\u2013942. https:\/\/doi.org\/10.1200\/JCO.2004.03.050","journal-title":"J Clin Oncol"},{"key":"4644_CR2","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/ajh.25011","volume":"93","author":"E Jabbour","year":"2018","unstructured":"Jabbour E, Kantarjian H (2018) Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol 93:442\u2013459. https:\/\/doi.org\/10.1002\/ajh.25011","journal-title":"Am J Hematol"},{"key":"4644_CR3","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1038\/leu.2009.88","volume":"23","author":"JE Cortes","year":"2009","unstructured":"Cortes JE, Egorin MJ, Guilhot F et al (2009) Pharmacokinetic\/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. Leukemia 23:1537\u20131544","journal-title":"Leukemia"},{"key":"4644_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/FTD.0B013E31823CDEC9","volume":"34","author":"JFT Teng","year":"2012","unstructured":"Teng JFT, Mabasa VH, Ensom MHH (2012) The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors. Ther Drug Monit 34:85\u201397. https:\/\/doi.org\/10.1097\/FTD.0B013E31823CDEC9","journal-title":"Ther Drug Monit"},{"key":"4644_CR5","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1248\/bpb.b15-00103","volume":"38","author":"M Miura","year":"2015","unstructured":"Miura M (2015) Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib for Patients with Chronic Myeloid Leukemia. Biol Pharm Bull 38:645\u2013654","journal-title":"Biol Pharm Bull"},{"key":"4644_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00603","author":"A Isidori","year":"2019","unstructured":"Isidori A, Tiribelli M, Iurlo A et al (2019) Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2019.00603","journal-title":"Front Oncol"},{"key":"4644_CR7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.4103\/0971-5851.123752","volume":"34","author":"B Arora","year":"2013","unstructured":"Arora B, Gota V, Menon H et al (2013) Therapeutic drug monitoring for imatinib: Current status and Indian experience. Ind J Med Paediat Oncol 34:224\u2013228. https:\/\/doi.org\/10.4103\/0971-5851.123752","journal-title":"Ind J Med Paediat Oncol"},{"key":"4644_CR8","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1016\/j.clinthera.2019.10.009","volume":"41","author":"M Garc\u00eda-Ferrer","year":"2019","unstructured":"Garc\u00eda-Ferrer M, Wojnicz A, Mej\u00eda G et al (2019) Utility of Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib in Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis. Clin Ther 41:2558-2570.e7","journal-title":"Clin Ther"},{"key":"4644_CR9","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/bcp.14185","volume":"86","author":"K Westerdijk","year":"2020","unstructured":"Westerdijk K, Desar IME, Steeghs N et al (2020) Imatinib, sunitinib and pazopanib: from flat-fixed dosing towards a pharmacokinetically guided personalized dose. Br J Clin Pharmacol 86:258\u2013273. https:\/\/doi.org\/10.1111\/bcp.14185","journal-title":"Br J Clin Pharmacol"},{"key":"4644_CR10","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1002\/cncr.32751","volume":"126","author":"Y Xia","year":"2020","unstructured":"Xia Y, Chen S, Meijuan et al (2020) Correlations Between Imatinib Plasma Trough Concentration and Adverse Reactions in Chinese Patients with Gastrointestinal Stromal Tumors. Cancer 126:2054\u20132061. https:\/\/doi.org\/10.1002\/cncr.32751","journal-title":"Cancer"},{"key":"4644_CR11","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1182\/BLOOD-2007-03-079871","volume":"110","author":"C Blasdel","year":"2007","unstructured":"Blasdel C, Egorin MJ, Lagattuta TF et al (2007) Therapeutic drug monitoring in CML patients on imatinib. Blood 110:1699\u20131701. https:\/\/doi.org\/10.1182\/BLOOD-2007-03-079871","journal-title":"Blood"},{"key":"4644_CR12","doi-asserted-by":"publisher","first-page":"5600","DOI":"10.1182\/BLOOD-2010-11-318949","volume":"117","author":"JE Cortes","year":"2011","unstructured":"Cortes JE, Hochhaus A, le Coutre PD et al (2011) Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. Blood 117:5600. https:\/\/doi.org\/10.1182\/BLOOD-2010-11-318949","journal-title":"Blood"},{"key":"4644_CR13","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1111\/j.1349-7006.2010.01643.x","volume":"101","author":"Y Ishikawa","year":"2010","unstructured":"Ishikawa Y, Kiyoi H, Watanabe K et al (2010) Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: A report from the BINGO study. Cancer Sci 101:2186\u20132192. https:\/\/doi.org\/10.1111\/j.1349-7006.2010.01643.x","journal-title":"Cancer Sci"},{"key":"4644_CR14","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/CLPT.2010.186","volume":"88","author":"N Takahashi","year":"2010","unstructured":"Takahashi N, Wakita H, Miura M et al (2010) Correlation Between Imatinib Pharmacokinetics and Clinical Response in Japanese Patients With Chronic-Phase Chronic Myeloid Leukemia. Clin Pharmacol Ther 88:809\u2013813. https:\/\/doi.org\/10.1038\/CLPT.2010.186","journal-title":"Clin Pharmacol Ther"},{"key":"4644_CR15","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.3109\/10428194.2011.563885","volume":"52","author":"SK Sohn","year":"2011","unstructured":"Sohn SK, Oh SJ, Kim BS et al (2011) Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia. Leuk Lymphoma 52:1024\u20131029. https:\/\/doi.org\/10.3109\/10428194.2011.563885","journal-title":"Leuk Lymphoma"},{"key":"4644_CR16","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1111\/bcp.15122","volume":"88","author":"\u00c1 Corral Alaejos","year":"2022","unstructured":"Corral Alaejos \u00c1, Zarzuelo Casta\u00f1eda A, Jim\u00e9nez Cabrera S et al (2022) External evaluation of population pharmacokinetic models of imatinib in adults diagnosed with chronic myeloid leukaemia. Br J Clin Pharmacol 88:1913\u20131924. https:\/\/doi.org\/10.1111\/bcp.15122","journal-title":"Br J Clin Pharmacol"},{"key":"4644_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/PSP.2013.14","author":"DR Mould","year":"2013","unstructured":"Mould DR, Upton RN (2013) Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development\u2014Part 2: Introduction to Pharmacokinetic Modeling Methods. CPT Pharmacometrics Syst Pharmacol. https:\/\/doi.org\/10.1038\/PSP.2013.14","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"4644_CR18","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s40495-018-0139-0","volume":"4","author":"S Nair","year":"2018","unstructured":"Nair S, Kong A-NT (2018) Emerging roles for clinical pharmacometrics in cancer precision medicine. Curr Pharmacol Rep 4:276\u2013283. https:\/\/doi.org\/10.1007\/s40495-018-0139-0","journal-title":"Curr Pharmacol Rep"},{"key":"4644_CR19","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/S00228-022-03345-8\/FIGURES\/3","volume":"78","author":"B Shriyan","year":"2022","unstructured":"Shriyan B, Mehta P, Patil A et al (2022) Role of ADME gene polymorphisms on imatinib disposition: results from a population pharmacokinetic study in chronic myeloid leukaemia. Eur J Clin Pharmacol 78:1321\u20131330. https:\/\/doi.org\/10.1007\/S00228-022-03345-8\/FIGURES\/3","journal-title":"Eur J Clin Pharmacol"},{"key":"4644_CR20","doi-asserted-by":"publisher","DOI":"10.1101\/2020.11.28.402297","author":"C Rackauckas","year":"2020","unstructured":"Rackauckas C, Ma Y, Noack A et al (2020) Accelerated Predictive Healthcare Analytics With Pumas. High Perform Pharmaceut Model Simulat Platf Preprint. https:\/\/doi.org\/10.1101\/2020.11.28.402297","journal-title":"High Perform Pharmaceut Model Simulat Platf Preprint"},{"key":"4644_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/BF01060893","author":"LB Sheiner","year":"1981","unstructured":"Sheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharmaceut. https:\/\/doi.org\/10.1007\/BF01060893","journal-title":"J Pharmacokinet Biopharmaceut"},{"key":"4644_CR22","first-page":"26","volume":"1","author":"MK-KBPASMMNME Ansari","year":"2016","unstructured":"Ansari MK-KBPASMMNME (2016) Population Pharmacokinetics of Imatinib and its application to the therapeutic drug monitoring: Middle East CML population. Gulf J Oncolog 1:26\u201336","journal-title":"Gulf J Oncolog"},{"key":"4644_CR23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00280-014-2473-1","volume":"74","author":"AA Golabchifar","year":"2014","unstructured":"Golabchifar AA, Rezaee S, Ghavamzadeh A et al (2014) Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia. Cancer Chemother Pharmacol 74:85\u201393. https:\/\/doi.org\/10.1007\/s00280-014-2473-1","journal-title":"Cancer Chemother Pharmacol"},{"key":"4644_CR24","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.leukres.2014.03.023","volume":"38","author":"V Gotta","year":"2014","unstructured":"Gotta V, Bouchet S, Widmer N et al (2014) Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions. Leuk Res 38:764\u2013772. https:\/\/doi.org\/10.1016\/j.leukres.2014.03.023","journal-title":"Leuk Res"},{"key":"4644_CR25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1365-2125.2005.02372.x","volume":"60","author":"H Schmidli","year":"2005","unstructured":"Schmidli H, Peng B, Riviere GJ et al (2005) Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: Results of a phase III study. Br J Clin Pharmacol 60:35\u201344. https:\/\/doi.org\/10.1111\/j.1365-2125.2005.02372.x","journal-title":"Br J Clin Pharmacol"},{"key":"4644_CR26","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2217\/pgs-2018-0139","volume":"20","author":"Q Wang","year":"2019","unstructured":"Wang Q, Jiang ZP, Yu EQ et al (2019) Population pharmacokinetic and pharmacogenetics of imatinib in Chinese patients with chronic myeloid leukemia. Pharmacogenomics 20:251\u2013260. https:\/\/doi.org\/10.2217\/pgs-2018-0139","journal-title":"Pharmacogenomics"},{"key":"4644_CR27","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1365-2125.2006.02719.x","volume":"62","author":"N Widmer","year":"2006","unstructured":"Widmer N, Decosterd LA, Csajka C et al (2006) Population pharmacokinetics of imatinib and the role of \u03b11-acid glycoprotein. Br J Clin Pharmacol 62:97\u2013112. https:\/\/doi.org\/10.1111\/j.1365-2125.2006.02719.x","journal-title":"Br J Clin Pharmacol"},{"key":"4644_CR28","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/FTD.0b013e31820beb02","volume":"33","author":"Y Yamakawa","year":"2011","unstructured":"Yamakawa Y, Hamada A, Nakashima R et al (2011) Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit 33:244\u201350. https:\/\/doi.org\/10.1097\/FTD.0b013e31820beb02","journal-title":"Ther Drug Monit"},{"key":"4644_CR29","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00280-008-0730-x","volume":"63","author":"D Menon-Andersen","year":"2009","unstructured":"Menon-Andersen D, Mondick JT, Jayaraman B et al (2009) Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults. Cancer Chemother Pharmacol 63:229\u2013238. https:\/\/doi.org\/10.1007\/s00280-008-0730-x","journal-title":"Cancer Chemother Pharmacol"},{"key":"4644_CR30","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1124\/DMD.122.000877","volume":"50","author":"S Cheng","year":"2022","unstructured":"Cheng S, Flora DR, Rettie AE et al (2022) Pharmacokinetic Modeling of Warfarin II \u2013 Model-Based Analysis of Warfarin Metabolites after Warfarin Administered Either Alone or Together with Fluconazole or Rifampin. Drug Metab Dispos 50:1302\u20131311. https:\/\/doi.org\/10.1124\/DMD.122.000877","journal-title":"Drug Metab Dispos"},{"key":"4644_CR31","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/BF01060893","volume":"9","author":"LB Sheiner","year":"1981","unstructured":"Sheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503\u2013512. https:\/\/doi.org\/10.1007\/BF01060893","journal-title":"J Pharmacokinet Biopharm"},{"key":"4644_CR32","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","volume":"44","author":"B Peng","year":"2005","unstructured":"Peng B, Lloyd P, Schran H (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44:879\u201394. https:\/\/doi.org\/10.2165\/00003088-200544090-00001","journal-title":"Clin Pharmacokinet"},{"key":"4644_CR33","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","volume":"28","author":"D Marin","year":"2010","unstructured":"Marin D, Bazeos A, Mahon FX et al (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28:2381\u20132388. https:\/\/doi.org\/10.1200\/JCO.2009.26.3087","journal-title":"J Clin Oncol"},{"key":"4644_CR34","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/tpj.2014.7","volume":"14","author":"A di Paolo","year":"2014","unstructured":"di Paolo A, Polillo M, Capecchi M et al (2014) The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia. Pharmacogenomics J 14:328\u2013335. https:\/\/doi.org\/10.1038\/tpj.2014.7","journal-title":"Pharmacogenomics J"},{"key":"4644_CR35","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1080\/10428194.2018.1485907","volume":"60","author":"H Natarajan","year":"2019","unstructured":"Natarajan H, Kumar L, Bakhshi S et al (2019) Imatinib trough levels: a potential biomarker to predict cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia. Leuk Lymphoma 60:418\u2013425. https:\/\/doi.org\/10.1080\/10428194.2018.1485907","journal-title":"Leuk Lymphoma"},{"key":"4644_CR36","unstructured":"24 Months Update of the TOPS Study: a Phase III, Randomized, Open-Label Study of 400mg\/d (SD-IM) Versus 800mg\/d (HD-IM) of Imatinib Mesylate (IM) in Patients (Pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP). | Elsevier Enhanced Reader. https:\/\/reader.elsevier.com\/reader\/sd\/pii\/S0006497119531500?token=E497E72DC2E139F2B905A57D9B2620952E51506C87894E827E273EFC703E3395DE5B148BE2CFDED75532D3A574AB50D0&originRegion=eu-west-1&originCreation=20220124104448. Accessed 24 Jan 2022"},{"key":"4644_CR37","doi-asserted-by":"publisher","unstructured":"Buclin T, Thoma Y, Widmer N et al (2020) The steps to therapeutic drug monitoring: a structured approach illustrated with imatinib. Front Pharmacol 11:177. https:\/\/doi.org\/10.3389\/fphar.2020.00177","DOI":"10.3389\/fphar.2020.00177"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04644-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-024-04644-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04644-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T14:02:50Z","timestamp":1721311370000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-024-04644-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,5]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["4644"],"URL":"https:\/\/doi.org\/10.1007\/s00280-024-04644-w","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,5]]},"assertion":[{"value":"12 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}